Hallmarks of therapeutic management of the cystic fibrosis functional landscape

Journal of Cystic Fibrosis

Volumn 14, Issue 6, 2015, Pages 687-699

  Amaral, Margarida D ^a   Balch, William E ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Bioinformatics; Chaperones; Cystic fibrosis; Epigenetics; Epiproteomics; Genomics; High content microscopy; High throughput screening; Mass spectrometry; Protein folding; Proteomics; Proteostasis; System biology

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HISTONE DEACETYLASE 7; PROTEIN VARIANT; SMALL INTERFERING RNA;

CELLS BY BODY ANATOMY; DISEASE COURSE; DNA MODIFICATION; DOWN REGULATION; GENE REPLACEMENT THERAPY; GENETIC CODE; GENOME; GENOMICS; GENOTYPE; ION TRANSPORT; LIPID BILAYER; NETWORK LEARNING; PERCEPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEOMICS; REVIEW; STRESS; STRUCTURE ACTIVITY RELATION; TRANSCRIPTOMICS; X RAY CRYSTALLOGRAPHY; CYSTIC FIBROSIS; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS;

EID: 84946403816     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.09.006     Document Type: Review

References (188)

1. Darwin C. On the Origin of Species by Means of Natural Selection 1859, J. Murray, London.
2. Wang X., Venable J., LaPointe P., Hutt D.M., Koulov A.V., Coppinger J., Gurkan C., Kellner W., Matteson J., Plutner H., Riordan J.R., Kelly J.W., Yates J.R., Balch W.E. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127:803-815.
3. Coppinger J.A., Hutt D.M., Razvi A., Koulov A.V., Pankow S., Yates J.R., Balch W.E. A chaperone trap contributes to the onset of cystic fibrosis. PLoS One 2012, 7.
4. Balch W.E., Roth D.M., Hutt D.M. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011, 3.
5. Amaral M.D. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. J Intern Med 2015, 277:155-166.
6. Cutting G.R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 2015, 16:45-56.
7. Sosnay P.R., Siklosi K.R., Van Goor F., Kaniecki K., Yu H., Sharma N., Ramalho A.S., Amaral M.D., Dorfman R., Zielenski J., Masica D.L., Karchin R., Millen L., Thomas P.J., Patrinos G.P., Corey M., Lewis M.H., Rommens J.M., Castellani C., Penland C.M., Cutting G.R. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013, 45:1160-1167.
8. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
9. Balch W.E., Sznajder J.I., Budinger S., Finley D., Laposky A.D., Cuervo A.M., Benjamin I.J., Barreiro E., Morimoto R.I., Postow L., Weissman A.M., Gail D., Banks-Schlegel S., Croxton T., Gan W. Malfolded protein structure and proteostasis in lung diseases. Am J Respir Crit Care Med 2014, 189:96-103.
10. Wolff S., Weissman J.S., Dillin A. Differential scales of protein quality control. Cell 2014, 157:52-64.
11. Brandvold K.R., Morimoto R.I. The chemical biology of molecular chaperones-implications for modulation of proteostasis. J Mol Biol 2015, 427:2931-2947.
12. Labbadia J., Morimoto R.I. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015, 84:435-464.
13. Ryno L.M., Wiseman R.L., Kelly J.W. Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr Opin Chem Biol 2013, 17:346-352.
14. Eisele Y.S., Monteiro C., Fearns C., Encalada S.E., Wiseman R.L., Powers E.T., Kelly J.W. Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 2015, [Epub ahead of print].
15. Wiseman R.L., Powers E.T., Buxbaum J.N., Kelly J.W., Balch W.E. An adaptable standard for protein export from the endoplasmic reticulum. Cell 2007, 131:809-821.
16. Wiseman R.L., Koulov A., Powers E., Kelly J.W., Balch W.E. Protein energetics in maturation of the early secretory pathway. Curr Opin Cell Biol 2007, 19:359-367.
17. Anfinsen C.B. Principles that govern the folding of protein chains. Science 1973, 181:223-230.
18. Powers E.T., Balch W.E. Diversity in the origins of proteostasis networks-a driver for protein function in evolution. Nat Rev Mol Cell Biol 2013, 14:237-248.
19. Awatade N.T., Uliyakina I., Farinha C.M., Clarke L.A., Mendes K., Sole A., Pastor J., Ramos M.M., Amaral M.D. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2015, 2:147-153.
20. Loureiro C.A., Matos A.M., Dias-Alves A., Pereira J.F., Uliyakina I., Barros P., Amaral M.D., Matos P. A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint. Sci Signal 2015, 8.
21. Roth D.M., Balch W.E. Modeling general proteostasis: proteome balance in health and disease. Curr Opin Cell Biol 2011, 23:126-134.
22. van Oosten-Hawle P., Morimoto R.I. Organismal proteostasis: role of cell-nonautonomous regulation and transcellular chaperone signaling. Genes Dev 2014, 28:1533-1543.
23. Roth D.M., Hutt D.M., Tong J., Bouchecareilh M., Wang N., Seeley T., Dekkers J.F., Beekman J.M., Garza D., Drew L., Masliah E., Morimoto R.I., Balch W.E. Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol 2014, 12.
24. Botelho H.M., Uliyakina I., Awatade N.T., Proenca M.C., Tischer C., Sirianant L., Kunzelmann K., Pepperkok R., Amaral M.D. Protein traffic disorders: an effective high-throughput fluorescence microscopy pipeline for drug discovery. Sci Rep 2015, 5:9038.
25. Lukacs G.L., Verkman A.S. CFTR: folding, misfolding and correcting the deltaF508 conformational defect. Trends Mol Med 2012, 18:81-91.
26. Phuan P.W., Veit G., Tan J.A., Finkbeiner W.E., Lukacs G.L., Verkman A.S. Potentiators of defective deltaF508-CFTR gating that do not interfere with corrector action. Mol Pharmacol 2015, 88:791-799.
27. Okiyoneda T., Veit G., Dekkers J.F., Bagdany M., Soya N., Xu H., Roldan A., Verkman A.S., Kurth M., Simon A., Hegedus T., Beekman J.M., Lukacs G.L. Mechanism-based corrector combination restores deltaF508-CFTR folding and function. Nat Chem Biol 2013, 9:444-454.
28. Rabeh W.M., Bossard F., Xu H., Okiyoneda T., Bagdany M., Mulvihill C.M., Du K., di Bernardo S., Liu Y., Konermann L., Roldan A., Lukacs G.L. Correction of both NBD1 energetics and domain interface is required to restore deltaF508 CFTR folding and function. Cell 2012, 148:150-163.
29. Plenge R.M., Scolnick E.M., Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013, 12:581-594.
30. Firth A.L., Menon T., Parker G.S., Qualls S.J., Lewis B.M., Ke E., Dargitz C.T., Wright R., Khanna A., Gage F.H., Verma I.M. Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient IPSCS. Cell Rep. 2015, 12:1385-1390.
31. Moss J.A. Gene therapy review. Radiol Technol 2014, 86:155-180. (quiz 181-154).
32. Gill D.R., Hyde S.C. Delivery of genes into the CF airway. Thorax 2014, 69:962-964.
33. Sahni N., Yi S., Taipale M., Fuxman Bass J.I., Coulombe-Huntington J., Yang F., Peng J., Weile J., Karras G.I., Wang Y., Kovacs I.A., Kamburov A., Krykbaeva I., Lam M.H., Tucker G., Khurana V., Sharma A., Liu Y.Y., Yachie N., Zhong Q., Shen Y., Palagi A., San-Miguel A., Fan C., Balcha D., Dricot A., Jordan D.M., Walsh J.M., Shah A.A., Yang X., Stoyanova A.K., Leighton A., Calderwood M.A., Jacob Y., Cusick M.E., Salehi-Ashtiani K., Whitesell L.J., Sunyaev S., Berger B., Barabasi A.L., Charloteaux B., Hill D.E., Hao T., Roth F.P., Xia Y., Walhout A.J., Lindquist S., Vidal M. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 2015, 161:647-660.
34. Griesenbach U., Alton E.W. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012, 18:642-662.
35. Thannickal V.J., Murthy M., Balch W.E., Chandel N.S., Meiners S., Eickelberg O., Selman M., Pardo A., White E.S., Levy B.D., Busse P.J., Tuder R.M., Antony V.B., Sznajder J.I., Budinger G.R. Blue journal conference, Aging and susceptibility to lung disease. Am J Respir Crit Care Med 2015, 191:261-269.
36. Hutt D.M., Roth D.M., Chalfant M.A., Youker R.T., Matteson J., Brodsky J.L., Balch W.E. Fk506 binding protein 8 peptidyl prolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability. J Biol Chem 2012, 287:21914-21925.
37. Mendes F., Farinha C.M., Felicio V., Alves P.C., Vieira I., Amaral M.D. Bag-1 stabilizes mutant F508del-CFTR in a ubiquitin-like-domain-dependent manner. Cell Physiol Biochem 2012, 30:1120-1133.
38. Farinha C.M., Nogueira P., Mendes F., Penque D., Amaral M.D. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by hsp70. Biochem J 2002, 366:797-806.
39. Grove D.E., Fan C.Y., Ren H.Y., Cyr D.M. The endoplasmic reticulum-associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate rma1 e3-dependent degradation of nascent CFTRdeltaF508. Mol Biol Cell 2011, 22:301-314.
40. Younger J.M., Chen L., Ren H.Y., Rosser M.F., Turnbull E.L., Fan C.Y., Patterson C., Cyr D.M. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell 2006, 126:571-582.
41. Ahner A., Gong X., Schmidt B.Z., Peters K.W., Rabeh W.M., Thibodeau P.H., Lukacs G.L., Frizzell R.A. Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol Biol Cell 2013, 24:74-84.
42. Schmidt B.Z., Watts R.J., Aridor M., Frizzell R.A. Cysteine string protein promotes proteasomal degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) by increasing its interaction with the c terminus of Hsp70-interacting protein and promoting CFTR ubiquitylation. J Biol Chem 2009, 284:4168-4178.
43. Ahner A., Nakatsukasa K., Zhang H., Frizzell R.A., Brodsky J.L. Small heat-shock proteins select deltaF508-CFTR for endoplasmic reticulum-associated degradation. Mol Biol Cell 2007, 18:806-814.
44. Zhang H., Schmidt B.Z., Sun F., Condliffe S.B., Butterworth M.B., Youker R.T., Brodsky J.L., Aridor M., Frizzell R.A. Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 2006, 281:11312-11321.
45. Sun F., Zhang R., Gong X., Geng X., Drain P.F., Frizzell R.A. Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants. J Biol Chem 2006, 281:36856-36863.
46. Heard A., Thompson J., Carver J., Bakey M., Wang X.R. Targeting molecular chaperones for the treatment of cystic fibrosis: is it a viable approach?. Curr Drug Targets 2015, 16:958-964.
47. Valastyan J.S., Lindquist S. Mechanisms of protein-folding diseases at a glance. Dis Model Mech 2014, 7:9-14.
48. LaBarge S., Migdal C., Schenk S. Is acetylation a metabolic rheostat that regulates skeletal muscle insulin action?. Mol Cells 2015, 38:297-303.
49. Hutt D.M., Powers E.T., Balch W.E. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett 2009, 2639-2646. %20;583.
50. Hutt D.M., Balch W.E. Expanding proteostasis by membrane trafficking networks. Cold Spring Harb Perspect Biol 2013, 5.
51. Labbadia J., Morimoto R.I. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015, 84:435-464.
52. Kim Y.E., Hipp M.S., Bracher A., Hayer-Hartl M., Hartl F.U. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem 2013, 82:323-355.
53. Hipp M.S., Park S.H., Hartl F.U. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol 2014, 24:506-514.
54. Young J.C. The role of the cytosolic Hsp70 chaperone system in diseases caused by misfolding and aberrant trafficking of ion channels. Dis Model Mech 2014, 7:319-329.
55. Oliveberg M., Wolynes P.G. The experimental survey of protein-folding energy landscapes. Q Rev Biophys 2005, 38:245-288.
56. Ferreiro D.U., Komives E.A., Wolynes P.G. Frustration in biomolecules. Q Rev Biophys 2014, 47:285-363.
57. Onuchic J.N., Luthey-Schulten Z., Wolynes P.G. Theory of protein folding: the energy landscape perspective. Annu Rev Phys Chem 1997, 48:545-600.
58. Farinha C.M., Matos P., Amaral M.D. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. FEBS J 2013, 280:4396-4406.
59. Rauniyar N., Gupta V., Balch W.E., Yates J.R. Quantitative proteomic profiling reveals differentially regulated proteins in cystic fibrosis cells. J Proteome Res 2014, 13:4668-4675.
60. Saxena A., Banasavadi-Siddegowda Y.K., Fan Y., Bhattacharya S., Roy G., Giovannucci D.R., Frizzell R.A., Wang X. Human heat shock protein 105/110kDa (Hsp105/110) regulates biogenesis and quality control of misfolded cystic fibrosis transmembrane conductance regulator at multiple levels. J Biol Chem 2012, 287:19158-19170.
61. Ahner A., Gong X., Frizzell R.A. Cystic fibrosis transmembrane conductance regulator degradation: Cross-talk between the ubiquitylation and sumoylation pathways. FEBS J 2013, 280:4430-4438.
62. Tran J.R., Tomsic L.R., Brodsky J.L. A cdc48p-associated factor modulates endoplasmic reticulum-associated degradation, cell stress, and ubiquitinated protein homeostasis. J Biol Chem 2011, 286:5744-5755.
63. Peters K.W., Okiyoneda T., Balch W.E., Braakman I., Brodsky J.L., Guggino W.B., Penland C.M., Pollard H.B., Sorscher E.J., Skach W.R., Thomas P.J., Lukacs G.L., Frizzell R.A. CFTR folding consortium: methods available for studies of CFTR folding and correction. Methods Mol Biol 2011, 742:335-353.
64. Du K., Lukacs G.L. Cooperative assembly and misfolding of CFTR domains in vivo. Mol Biol Cell 2009, 20:1903-1915.
65. Hoelen H., Kleizen B., Schmidt A., Richardson J., Charitou P., Thomas P.J., Braakman I. The primary folding defect and rescue of deltaF508 CFTR emerge during translation of the mutant domain. PLoS One 2010, 5.
66. Kim S.J., Yoon J.S., Shishido H., Yang Z., Rooney L.A., Barral J.M., Skach W.R. Protein folding. Translational tuning optimizes nascent protein folding in cells. Science 2015, 348:444-448.
67. Koulov A.V., LaPointe P., Lu B., Razvi A., Coppinger J., Dong M.Q., Matteson J., Laister R., Arrowsmith C., Yates J.R., Balch W.E. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell 2010, 21:871-884.
68. Nunes J.M., Mayer-Hartl M., Hartl F.U., Muller D.J. Action of the Hsp70 chaperone system observed with single proteins. Nat Commun 2015, 6:6307-6312.
69. Matsumura Y., David L.L., Skach W.R. Role of Hsc70 binding cycle in CFTR folding and endoplasmic reticulum-associated degradation. Mol Biol Cell 2011, 22:2797-2809.
70. MacGurn J.A., Hsu P.C., Emr S.D. Ubiquitin and membrane protein turnover: from cradle to grave. Annu Rev Biochem 2012, 81:231-259.
71. Hutt D.M., Powers E.T., Balch W.E. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett 2009, 583:2639-2646.
72. Turnbull E.L., Rosser M.F., Cyr D.M. The role of the ups in cystic fibrosis. BMC Biochem 2007, 8(Suppl. 1):S11.
73. Matsumura Y., Sakai J., Skach W.R. Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/C70 protein and the chip e3 ligase. J Biol Chem 2013, 288:31069-31079.
74. Barriere H., Apaja P., Okiyoneda T., Lukacs G.L. Endocytic sorting of CFTR variants monitored by single-cell fluorescence ratiometric image analysis (FRIA) in living cells. Methods Mol Biol 2011, 741:301-317.
75. Valentine C.D., Lukacs G.L., Verkman A.S., Haggie P.M. Reduced PDZ interactions of rescued deltaF508CFTR increases its cell surface mobility. J Biol Chem 2012, 287:43630-43638.
76. De Stefano D., Villella V.R., Esposito S., Tosco A., Sepe A., De Gregorio F., Salvadori L., Grassia R., Leone C.A., De Rosa G., Maiuri M.C., Pettoello-Mantovani M., Guido S., Bossi A., Zolin A., Venerando A., Pinna L.A., Mehta A., Bona G., Kroemer G., Maiuri L., Raia V. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy 2014, 10:2053-2074.
77. Nillegoda N.B., Kirstein J., Szlachcic A., Berynskyy M., Stank A., Stengel F., Arnsburg K., Gao X., Scior A., Aebersold R., Guilbride D.L., Wade R.C., Morimoto R.I., Mayer M.P., Bukau B. Crucial Hsp70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 2015, 524:247-251.
78. Walther D.M., Kasturi P., Zheng M., Pinkert S., Vecchi G., Ciryam P., Morimoto R.I., Dobson C.M., Vendruscolo M., Mann M., Hartl F.U. Widespread proteome remodeling and aggregation in aging C. elegans. Cell 2015, 161:919-932.
79. Brehme M., Voisine C., Rolland T., Wachi S., Soper J.H., Zhu Y., Orton K., Villella A., Garza D., Vidal M., Ge H., Morimoto R.I. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep. 2014, 9:1135-1150.
80. Zalatan J.G., Lee M.E., Almeida R., Gilbert L.A., Whitehead E.H., La Russa M., Tsai J.C., Weissman J.S., Dueber J.E., Qi L.S., Lim W.A. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 2015, 160:339-350.
81. Jan C.H., Williams C.C., Weissman J.S. Principles of er cotranslational translocation revealed by proximity-specific ribosome profiling. Science 2014, 346:1257521.
82. Balch W.E., Yates J.R. III Application of mass spectrometry to study proteomics and interactomics in cystic fibrosis. Methods Mol Biol 2011, 742:227-247. 10.1007/978-1-61779-120-8_14, 227-247.
83. Rauniyar N., Yates J.R. Isobaric labeling-based relative quantification in shotgun proteomics. J Proteome Res 2014, 13:5293-5309.
84. Zhang Y., Fonslow B.R., Shan B., Baek M.C., Yates J.R. Protein analysis by shotgun/bottom-up proteomics. Chem Rev 2013, 113:2343-2394.
85. Cox J., Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 2011, 80:273-299.
86. Weekes M.P., Tomasec P., Huttlin E.L., Fielding C.A., Nusinow D., Stanton R.J., Wang E.C., Aicheler R., Murrell I., Wilkinson G.W., Lehner P.J., Gygi S.P. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 2014, 157:1460-1472.
87. Colas J., Faure G., Saussereau E., Trudel S., Rabeh W.M., Bitam S., Guerrera I.C., Fritsch J., Sermet-Gaudelus I., Davezac N., Brouillard F., Lukacs G.L., Herrmann H., Ollero M., Edelman A. Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect. Hum Mol Genet 2012, 21:623-634.
88. Guerrera I.C., Ollero M., Vieu D.L., Edelman A. Quantitative differential proteomics of cystic fibrosis cell models by silac (stable isotope labelling in cell culture). Methods Mol Biol 2011, 742:213-225.
89. McShane A.J., Bajrami B., Ramos A.A., Diego-Limpin P.A., Farrokhi V., Coutermarsh B.A., Stanton B.A., Jensen T., Riordan J.R., Wetmore D., Joseloff E., Yao X. Targeted proteomic quantitation of the absolute expression and turnover of cystic fibrosis transmembrane conductance regulator in the apical plasma membrane. J Proteome Res 2014, 13:4676-4685.
90. Dephoure N., Gould K.L., Gygi S.P., Kellogg D.R. Mapping and analysis of phosphorylation sites: a quick guide for cell biologists. Mol Biol Cell 2013, 24:535-542.
91. Olsen J.V., Mann M. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics 2013, 12:3444-3452.
92. Scholz C., Weinert B.T., Wagner S.A., Beli P., Miyake Y., Qi J., Jensen L.J., Streicher W., McCarthy A.R., Westwood N.J., Lain S., Cox J., Matthias P., Mann M., Bradner J.E., Choudhary C. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol 2015, 33:415-423.
93. Hutt D.M., Herman D., Rodrigues A.P., Noel S., Pilewski J.M., Matteson J., Hoch B., Kellner W., Kelly J.W., Schmidt A., Thomas P.J., Matsumura Y., Skach W.R., Gentzsch M., Riordan J.R., Sorscher E.J., Okiyoneda T., Yates J.R., Lukacs G.L., Frizzell R.A., Manning G., Gottesfeld J.M., Balch W.E. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010, 6:25-33.
94. Lavallee-Adam M., Rauniyar N., McClatchy D.B., Yates J.R. PSEA-Quant: a protein set enrichment analysis on label-free and label-based protein quantification data. J Proteome Res 2014, 13:5496-5509.
95. Edelman A. Cytoskeleton and CFTR. Int J Biochem Cell Biol 2014, 52:68-72.
96. Jeanson L., Guerrera I.C., Papon J.F., Chhuon C., Zadigue P., Pruliere-Escabasse V., Amselem S., Escudier E., Coste A., Edelman A. Proteomic analysis of nasal epithelial cells from cystic fibrosis patients. PLoS One 2014, 9.
97. Quon B.S., Dai D.L., Hollander Z., Ng R.T., Tebbutt S.J., Man S.F., Wilcox P.G., Sin D.D. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax 2015, [Epub ahead of print].
98. Joo N.S., Evans I.A., Cho H.J., Park I.H., Engelhardt J.F., Wine J.J. Proteomic analysis of pure human airway gland mucus reveals a large component of protective proteins. PLoS One 2015, 10.
99. Peters-Hall J.R., Brown K.J., Pillai D.K., Tomney A., Garvin L.M., Wu X., Rose M.C. Quantitative proteomics reveals an altered cystic fibrosis in vitro bronchial epithelial secretome. Am J Respir Cell Mol Biol 2015, 53:22-32.
100. Stutts M.J., Canessa C.M., Olsen J.C., Hamrick M., Cohn J.A., Rossier B.C., Boucher R.C. CFTR as a camp-dependent regulator of sodium channels. Science 1995, 269:847-850.
101. + conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 1998, 102:15-21.
102. Mall M., Wissner A., Schreiber R., Kuehr J., Seydewitz H.H., Brandis M., Greger R., Kunzelmann K. Role of K(V)LQT1 in cyclic adenosine monophosphate-mediated Cl(-) secretion in human airway epithelia. Am J Respir Cell Mol Biol 2000, 23:283-289.
103. Jourdain P., Becq F., Lengacher S., Boinot C., Magistretti P.J., Marquet P. The human CFTR protein expressed in CHO cells activates aquaporin-3 in a camp-dependent pathway: study by digital holographic microscopy. J Cell Sci 2014, 127:546-556.
104. - channels. Cell Physiol Biochem 2011, 28:715-724.
105. Kunzelmann K. CFTR: interacting with everything?. News Physiol Sci 2001, 16:167-170.
106. - secretion. Int. J. Biochem. Cell Biol. 2012, 44:1897-1900.
107. l, K.E., Toure A. Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the slc26 family of anion transporters (slc26a8 and slc26a9): physiological and pathophysiological relevance. Int. J. Biochem. Cell Biol. 2014, 52:58-67. (Epub;%2014 Feb 14., 58-67). 10.1016/j.biocel.2014.02.001.
108. Ko S.B., Shcheynikov N., Choi J.Y., Luo X., Ishibashi K., Thomas P.J., Kim J.Y., Kim K.H., Lee M.G., Naruse S., Muallem S. A molecular mechanism for aberrant CFTR-dependent HCO(3)(-) transport in cystic fibrosis. EMBO J 2002, 21:5662-5672.
109. Jang Y., Oh U. Anoctamin 1 in secretory epithelia. Cell Calcium 2014, 55:355-361.
110. Caohuy H., Yang Q., Eudy Y., Ha T.A., Xu A.E., Glover M., Frizzell R.A., Jozwik C., Pollard H.B. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of deltaF508-cystic fibrosis transmembrane conductance regulator (deltaF508-CFTR). J Biol Chem 2014, 289:35953-35968.
111. Chambers L.A., Rollins B.M., Tarran R. Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol 2007, 159:256-270.
112. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007, 58:157-170.
113. Kreda S.M., Davis C.W., Rose M.C. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb. Perspect. Med. 2012, 2:a009589.
114. Ballard S.T., Spadafora D. Fluid secretion by submucosal glands of the tracheobronchial airways. Respir Physiol Neurobiol 2007, 159:271-277.
115. Shamsuddin A.K., Quinton P.M. Native small airways secrete bicarbonate. Am J Respir Cell Mol Biol 2014, 50:796-804.
116. Quinton P.M. Too much salt, too little soda: cystic fibrosis. Sheng Li Xue Bao 2007, 59:397-415.
117. Collawn J.F., Fu L., Bartoszewski R., Matalon S. Rescuing deltaF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. Am J Physiol Lung Cell Mol Physiol 2014, 307:L431-L434.
118. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18:509-519.
119. Cantin A.M., Hartl D., Konstan M.W., Chmiel J.F. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015, 10.
120. Hajj R., Lesimple P., Nawrocki-Raby B., Birembaut P., Puchelle E., Coraux C. Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis. J Pathol 2007, 211:340-350.
121. Zhang J.T., Jiang X.H., Xie C., Cheng H., Da D.J., Wang Y., Fok K.L., Zhang X.H., Sun T.T., Tsang L.L., Chen H., Sun X.J., Chung Y.W., Cai Z.M., Jiang W.G., Chan H.C. Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta 2013, 1833:2961-2969.
122. Proctor E.A., Kota P., Aleksandrov A.A., He L., Riordan J.R., Dokholyan N.V. Rational coupled dynamics network manipulation rescues disease-relevant mutant cystic fibrosis transmembrane conductance regulator. Chem. Sci. 2015, 6:1237-1246.
123. Almaca J., Faria D., Sousa M., Uliyakina I., Conrad C., Sirianant L., Clarke L.A., Martins J.P., Santos M., Heriche J.K., Huber W., Schreiber R., Pepperkok R., Kunzelmann K., Amaral M.D. High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets. Cell 2013, 154:1390-1400.
124. Trzcinska-Daneluti A.M., Chen A., Nguyen L., Murchie R., Jiang C., Moffat J., Pelletier L., Rotin D. RNA interference screen to identify kinases that suppress rescue of deltaF508-CFTR. Mol Cell Proteomics 2015, 14:1569-1583. (mcp).
125. Trzcinska-Daneluti A.M., Ly D., Huynh L., Jiang C., Fladd C., Rotin D. High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteomics 2009, 8:780-790.
126. Dekkers J.F., Wiegerinck C.L., de Jonge H.R., Bronsveld I., Janssens H.M., de Winter-de Groot K.M., Brandsma A.M., de Jong N.W., Bijvelds M.J., Scholte B.J., Nieuwenhuis E.E., van den Brink S., Clevers H., van der Ent C.K., Middendorp S., Beekman J.M. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013, 19:939-945.
127. Wiemann S., Arlt D., Huber W., Wellenreuther R., Schleeger S., Mehrle A., Bechtel S., Sauermann M., Korf U., Pepperkok R., Sultmann H., Poustka A. From ORFeome to biology: a functional genomics pipeline. Genome Res 2004, 14:2136-2144.
128. Pepperkok R., Ellenberg J. High-throughput fluorescence microscopy for systems biology. Nat Rev Mol Cell Biol 2006, 7:690-696.
129. Neumann B., Held M., Liebel U., Erfle H., Rogers P., Pepperkok R., Ellenberg J. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods 2006, 3:385-390.
130. Larsen M.B., Hu J., Frizzell R.A., Watkins S.C. Simple image-based no-wash method for quantitative detection of surface expressed CFTR. Methods 2015 Sep 7, pii: S1046-2023(15)30079-7. doi:10.1016/j.ymeth.2015.09.006. [Epub ahead of print].
131. Lamont F.R., Tomlinson D.C., Cooper P.A., Shnyder S.D., Chester J.D., Knowles M.A. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011, 104:75-82.
132. Amaral M.D., Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007, 28:334-341.
133. Almaa J., Dahimene S., Appel N., Conrad C., Kunzelmann K., Pepperkok R., Amaral M.D. Functional genomics assays to study CFTR traffic and ENAC function. Methods Mol Biol 2011, 742:249-264.
134. Wachsmuth M., Conrad C., Bulkescher J., Koch B., Mahen R., Isokane M., Pepperkok R., Ellenberg J. High-throughput fluorescence correlation spectroscopy enables analysis of proteome dynamics in living cells. Nat Biotechnol 2015, 33:384-389.
135. O'Shea D., O'Connell J. Cystic fibrosis related diabetes. Curr Diab Rep 2014, 14:511.
136. Hegyi P., Rakonczay Z. The role of pancreatic ducts in the pathogenesis of acute pancreatitis. Pancreatology 2015, 10.
137. Javier R.M., Jacquot J. Bone disease in cystic fibrosis: what's new?. Joint Bone Spine 2011, 78:445-450.
138. Rato L., Socorro S., Cavaco J.E., Oliveira P.F. Tubular fluid secretion in the seminiferous epithelium: ion transporters and aquaporins in Sertoli cells. J Membr Biol 2010, 236:215-224.
139. Brandvold K.R., Morimoto R.I. The chemical biology of molecular chaperones - implications for modulation of proteostasis. J Mol Biol 2015, 427:2931-2947.
140. Taylor R.C., Dillin A. Aging as an event of proteostasis collapse. Cold Spring Harb Perspect Biol 2011, 3.
141. Vilchez D., Simic M.S., Dillin A. Proteostasis and aging of stem cells. Trends Cell Biol 2014, 24:161-170.
142. Clarke L.A., Sousa L., Barreto C., Amaral M.D. Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies. Respir Res 2013, 14:38.
143. Cusanovich D.A., Daza R., Adey A., Pliner H.A., Christiansen L., Gunderson K.L., Steemers F.J., Trapnell C., Shendure J. Epigenetics. Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Science 2015, 348:910-914.
144. Romanoski C.E., Glass C.K., Stunnenberg H.G., Wilson L., Almouzni G. Epigenomics: roadmap for regulation. Nature 2015, 518:314-316.
145. Skipper M., Eccleston A., Gray N., Heemels T., Le Bot N., Marte B., Weiss U. Presenting the epigenome roadmap. Nature 2015, 518:313.
146. Mele M., Ferreira P.G., Reverter F., DeLuca D.S., Monlong J., Sammeth M., Young T.R., Goldmann J.M., Pervouchine D.D., Sullivan T.J., Johnson R., Segre A.V., Djebali S., Niarchou A., Wright F.A., Lappalainen T., Calvo M., Getz G., Dermitzakis E.T., Ardlie K.G., Guigo R. Human genomics. The human transcriptome across tissues and individuals. Science 2015, 348:660-665.
147. Human genomics. The genotype-tissue expression (gtex) pilot analysis: multitissue gene regulation in humans. Science 2015, 348:648-660.
148. Gibson G. Human genetics. Gtex detects genetic effects. Science 2015, 348:640-641.
149. Singleton A.B., Traynor B.J. Genetics. For complex disease genetics, collaboration drives progress. Science 2015, 347:1422-1423.
150. Arner E., Daub C.O., Vitting-Seerup K., Andersson R., Lilje B., Drablos F., Lennartsson A., Ronnerblad M., Hrydziuszko O., Vitezic M., Freeman T.C., Alhendi A.M., Arner P., Axton R., Baillie J.K., Beckhouse A., Bodega B., Briggs J., Brombacher F., Davis M., Detmar M., Ehrlund A., Endoh M., Eslami A., Fagiolini M., Fairbairn L., Faulkner G.J., Ferrai C., Fisher M.E., Forrester L., Goldowitz D., Guler R., Ha T., Hara M., Herlyn M., Ikawa T., Kai C., Kawamoto H., Khachigian L.M., Klinken S.P., Kojima S., Koseki H., Klein S., Mejhert N., Miyaguchi K., Mizuno Y., Morimoto M., Morris K.J., Mummery C., Nakachi Y., Ogishima S., Okada-Hatakeyama M., Okazaki Y., Orlando V., Ovchinnikov D., Passier R., Patrikakis M., Pombo A., Qin X.Y., Roy S., Sato H., Savvi S., Saxena A., Schwegmann A., Sugiyama D., Swoboda R., Tanaka H., Tomoiu A., Winteringham L.N., Wolvetang E., Yanagi-Mizuochi C., Yoneda M., Zabierowski S., Zhang P., Abugessaisa I., Bertin N., Diehl A.D., Fukuda S., Furuno M., Harshbarger J., Hasegawa A., Hori F., Ishikawa-Kato S., Ishizu Y., Itoh M., Kawashima T., Kojima M., Kondo N., Lizio M., Meehan T.F., Mungall C.J., Murata M., Nishiyori-Sueki H., Sahin S., Nagao-Sato S., Severin J., de Hoon M.J., Kawai J., Kasukawa T., Lassmann T., Suzuki H., Kawaji H., Summers K.M., Wells C., Hume D.A., Forrest A.R., Sandelin A., Carninci P., Hayashizaki Y. Gene regulation. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science 2015, 347:1010-1014.
151. Battle A., Khan Z., Wang S.H., Mitrano A., Ford M.J., Pritchard J.K., Gilad Y. Genomic variation. Impact of regulatory variation from RNA to protein. Science 2015, 347:664-667.
152. Ramachandran S., Clarke L.A., Scheetz T.E., Amaral M.D., McCray P.B. Microarray MRNA expression profiling to study cystic fibrosis. Methods Mol Biol 2011, 742:193-212.
153. Freedman, D.H. The streetlight effect. Discover magazine July-August (2010).
154. De Boeck K., Kent L., Davies J., Derichs N., Amaral M., Rowe S.M., Middleton P., de Jonge H., Bronsveld I., Wilschanski M., Melotti P., Danner-Boucher I., Boerner S., Fajac I., Southern K., de Nooijer R.A., Bot A., de Rijke Y., de Wachter E., Leal T., Vermeulen F., Hug M.J., Rault G., Nguyen-Khoa T., Barreto C., Proesmans M., Sermet-Gaudelus I. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013, 41:203-216.
155. Beekman J.M., Sermet-Gaudelus I., de Boeck K., Gonska T., Derichs N., Mall M.A., Mehta A., Martin U., Drumm M., Amaral M.D. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. J Cyst Fibros 2014, 13:363-372.
156. Wainwright C.E., Elborn J.S., Ramsey B.W., Marigowda G., Huang X., Cipolli M., Colombo C., Davies J.C., De Boeck K., Flume P.A., Konstan M.W., McColley S.A., McCoy K., McKone E.F., Munck A., Ratjen F., Rowe S.M., Waltz D., Boyle M.P. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015, 373:220-231.
157. Eckford P.D., Ramjeesingh M., Molinski S., Pasyk S., Dekkers J.F., Li C., Ahmadi S., Ip W., Chung T.E., Du K., Yeger H., Beekman J., Gonska T., Bear C.E. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 2014, 21:666-678.
158. Ren H.Y., Grove D.E., De La Rosa O., Houck S.A., Sopha P., Van Goor F., Hoffman B.J., Cyr D.M. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013, 24:3016-3024.
159. U.S.Vertex Food and drug administration approves KALYDECO™ (ivacaftor) for use in eight additional mutations that cause cystic fibrosis (press release). http://investors.vrtx.com/releasedetail.cfm?ReleaseID=827435.
160. Yu H., Burton B., Huang C.J., Worley J., Cao D., Johnson J.P., Urrutia A., Joubran J., Seepersaud S., Sussky K., Hoffman B.J., Van Goor F. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012, 11:237-245.
161. Wainwright C.E. Ivacaftor for patients with cystic fibrosis. Expert Rev Respir Med 2014, 8:533-538.
162. Van Goor F., Yu H., Burton B., Hoffman B.J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014, 13:29-36.
163. Moss R.B., Flume P.A., Elborn J.S., Cooke J., Rowe S.M., McColley S.A., Rubenstein R.C., Higgins M., Group V.X.S. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir. Med. 2015, 3:524-533.
164. Sinha C., Zhang W., Moon C.S., Actis M., Yarlagadda S., Arora K., Woodroofe K., Clancy J.P., Lin S., Ziady A.G., Frizzell R., Fujii N., Naren A.P. Capturing the direct binding of CFTR correctors to CFTR by using click chemistry. Chembiochem 2015, 16:2017-2022.
165. Yu W., Kim Chiaw P., Bear C.E. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant. J Biol Chem 2011, 286:24714-24725.
166. Loo T.W., Bartlett M.C., Clarke D.M. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem Pharmacol 2013, 86:612-619.
167. Cholon D.M., Quinney N.L., Fulcher M.L., Esther C.R., Das J., Dokholyan N.V., Randell S.H., Boucher R.C., Gentzsch M. Potentiator ivacaftor abrogates pharmacological correction of deltaF508 CFTR in cystic fibrosis. Sci Transl Med 2014, 6.
168. Veit G., Avramescu R.G., Perdomo D., Phuan P.W., Bagdany M., Apaja P.M., Borot F., Szollosi D., Wu Y.S., Finkbeiner W.E., Hegedus T., Verkman A.S., Lukacs G.L. Some gating potentiators, including VX-770, diminish deltaF508-CFTR functional expression. Sci Transl Med 2014, 6.
169. Eckford P.D., Li C., Ramjeesingh M., Bear C.E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but atp-independent manner. J Biol Chem 2012, 287:36639-36649.
170. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011, 10:328-329.
171. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011, 10:87.
172. Schreiber S.L., Kotz J.D., Li M., Aube J., Austin C.P., Reed J.C., Rosen H., White E.L., Sklar L.A., Lindsley C.W., Alexander B.R., Bittker J.A., Clemons P.A., de Souza A., Foley M.A., Palmer M., Shamji A.F., Wawer M.J., McManus O., Wu M., Zou B., Yu H., Golden J.E., Schoenen F.J., Simeonov A., Jadhav A., Jackson M.R., Pinkerton A.B., Chung T.D., Griffin P.R., Cravatt B.F., Hodder P.S., Roush W.R., Roberts E., Chung D.H., Jonsson C.B., Noah J.W., Severson W.E., Ananthan S., Edwards B., Oprea T.I., Conn P.J., Hopkins C.R., Wood M.R., Stauffer S.R., Emmitte K.A. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell 2015, 161:1252-1265.
173. Amaral M.D., Farinha C.M. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 2013, 19:3497-3508.
174. Phuan P.W., Veit G., Tan J., Roldan A., Finkbeiner W.E., Lukacs G.L., Verkman A.S. Synergy-based small-molecule screen using a human lung epithelial cell line yields deltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol 2014, 86:42-51.
175. Odolczyk N., Fritsch J., Norez C., Servel N., da Cunha M.F., Bitam S., Kupniewska A., Wiszniewski L., Colas J., Tarnowski K., Tondelier D., Roldan A., Saussereau E.L., Melin-Heschel P., Wieczorek G., Lukacs G.L., Dadlez M., Faure G., Herrmann H., Ollero M., Becq F., Zielenkiewicz P., Edelman A. Discovery of novel potent deltaF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med 2013, 5:1484-1501.
176. Okiyoneda T., Lukacs G.L. Fixing cystic fibrosis by correcting CFTR domain assembly. J Cell Biol 2012, 199:199-204.
177. Mendoza J.L., Schmidt A., Li Q., Nuvaga E., Barrett T., Bridges R.J., Feranchak A.P., Brautigam C.A., Thomas P.J. Requirements for efficient correction of deltaF508 CFTR revealed by analyses of evolved sequences. Cell 2012, 148:164-174.
178. Lindquist S.L., Kelly J.W. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol 2011, 3.
179. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998, 396:336-342.
180. 3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther 2015, 14:642-648.
181. Fontaine S.N., Martin M.D., Akoury E., Assimon V.A., Borysov S., Nordhues B.A., Sabbagh J.J., Cockman M., Gestwicki J.E., Zweckstetter M., Dickey C.A. The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet 2015, 24:3971-3981.
182. 3 interactions regulate cancer-related signaling networks. Cancer Res 2014, 74:4731-4740.
183. Assimon V.A., Gillies A.T., Rauch J.N., Gestwicki J.E. Hsp70 protein complexes as drug targets. Curr Pharm Des 2013, 19:404-417.
184. Pratt W.B., Gestwicki J.E., Osawa Y., Lieberman A.P. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2015, 55:353-371.
185. Taldone T., Ochiana S.O., Patel P.D., Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci 2014, 35:592-603.
186. Sinha M., Jang Y.C., Oh J., Khong D., Wu E.Y., Manohar R., Miller C., Regalado S.G., Loffredo F.S., Pancoast J.R., Hirshman M.F., Lebowitz J., Shadrach J.L., Cerletti M., Kim M.J., Serwold T., Goodyear L.J., Rosner B., Lee R.T., Wagers A.J. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014, 344:649-652.
187. Lamech L.T., Haynes C.M. The unpredictability of prolonged activation of stress response pathways. J Cell Biol 2015, 209:781-787.
188. Corvol H., Blackman S.M., Boelle P.Y., Gallins P.J., Pace R.G., Stonebraker J.R., Accurso F.J., Clement A., Collaco J.M., Dang H., Dang A.T., Franca A., Gong J., Guillot L., Keenan K., Li W., Lin F., Patrone M.V., Raraigh K.S., Sun L., Zhou Y.H., O'Neal W.K., Sontag M.K., Levy H., Durie P.R., Rommens J.M., Drumm M.L., Wright F.A., Strug L.J., Cutting G.R., Knowles M.R. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun 2015, 6:8382.